Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Source: 
BioCentury
snippet: 

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in preclinical models.